Home ETF List About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for PRAX

Stock NamePraxis Precision Medicines Inc
TickerPRAX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS74006W1080

Show aggregate PRAX holdings

News associated with PRAX

Praxis Precision Medicines (NASDAQ:PRAX) Raised to “Strong-Buy” at Lifesci Capital
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) was upgraded by equities research analysts at Lifesci Capital to a “strong-buy” rating in a report issued on Wednesday,Zacks.com reports. PRAX has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and issued a $115.00 price objective (up previously from […] - 2025-09-05 05:03:08
Brokerages Set Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Price Target at $85.88
Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average twelve-month target […] - 2025-08-20 02:55:14
Notable Thursday Option Activity: ADBE, SOC, PRAX
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Adobe Inc (Symbol: ADBE), where a total of 32,666 contracts have traded so far, representing approximately 3.3 million underlying shares. That amounts to about 74.3% of - 2025-07-17 16:34:10
Praxis Precision Medicines (NASDAQ:PRAX) Shares Up 10.4% Following Analyst Upgrade
Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report)’s share price rose 10.4% during trading on Wednesday after Oppenheimer raised their price target on the stock from $97.00 to $115.00. Oppenheimer currently has an outperform rating on the stock. Praxis Precision Medicines traded as high as $51.36 and last traded at $51.63. Approximately 285,956 shares […] - 2025-07-11 02:22:49
Brokerages Set Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Target Price at $109.90
Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average 1-year target price […] - 2025-07-01 03:06:54
Analysts Set Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Price Target at $109.90
Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report) has received a consensus rating of “Moderate Buy” from the ten research firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and nine have assigned a buy recommendation to the company. The average 12 month price […] - 2025-06-06 02:28:56
Squarepoint Ops LLC Reduces Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)
Squarepoint Ops LLC decreased its holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) by 46.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,782 shares of the company’s stock after selling 6,876 shares during the quarter. Squarepoint Ops LLC’s […] - 2025-06-04 05:04:49
Oppenheimer Begins Coverage on Praxis Precision Medicines (NASDAQ:PRAX)
Analysts at Oppenheimer started coverage on shares of Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) in a research note issued on Monday, Marketbeat Ratings reports. The firm set an “outperform” rating and a $97.00 price target on the stock. Oppenheimer’s price objective would indicate a potential upside of 135.44% from the stock’s previous close. […] - 2025-06-04 02:42:45
Man Group plc Sells 1,209 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)
Man Group plc reduced its stake in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) by 29.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,832 shares of the company’s stock after selling 1,209 shares during […] - 2025-05-28 05:36:51
ProShare Advisors LLC Makes New Investment in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)
ProShare Advisors LLC purchased a new stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) during the fourth quarter, HoldingsChannel reports. The institutional investor purchased 5,738 shares of the company’s stock, valued at approximately $442,000. A number of other hedge funds also recently made changes to their positions in PRAX. Barclays PLC boosted its […] - 2025-05-28 04:54:52
D. E. Shaw & Co. Inc. Increases Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)
D. E. Shaw & Co. Inc. lifted its position in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) by 3.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,993 shares of the company’s stock after acquiring an additional 1,629 shares […] - 2025-05-19 05:10:52
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives $116.50 Average Target Price from Brokerages
Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report) have earned an average recommendation of “Moderate Buy” from the ten research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The average […] - 2025-05-12 02:39:03
Voya Investment Management LLC Trims Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)
Voya Investment Management LLC lowered its position in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) by 7.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,228 shares of the company’s stock after selling 441 shares during the quarter. Voya […] - 2025-05-11 05:35:04
Needham & Company LLC Reiterates Buy Rating for Praxis Precision Medicines (NASDAQ:PRAX)
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Needham & Company LLC in a report released on Monday,Benzinga reports. They currently have a $80.00 target price on the stock. Needham & Company LLC’s target price would indicate a potential upside of 127.47% from the stock’s previous […] - 2025-05-07 02:58:50
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Purchased by Wells Fargo & Company MN
Wells Fargo & Company MN increased its position in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) by 46.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 8,612 shares of the company’s stock after acquiring an additional 2,746 shares during the quarter. Wells Fargo & Company MN’s holdings in Praxis Precision […] - 2025-05-02 04:22:58
Invesco Ltd. Has $6.69 Million Stock Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)
Invesco Ltd. cut its position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) by 19.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 86,983 shares of the company’s stock after selling 20,730 shares during the quarter. Invesco Ltd. owned approximately 0.47% of […] - 2025-04-25 05:08:54
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Recommendation of “Moderate Buy” from Brokerages
Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the nine analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and eight have issued a buy rating on the company. The […] - 2025-04-14 02:10:53
Critical Comparison: Praxis Precision Medicines (NASDAQ:PRAX) versus Sycamore Entertainment Group (OTCMKTS:SEGI)
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) and Sycamore Entertainment Group (OTCMKTS:SEGI – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk. Profitability This table compares Praxis […] - 2025-04-08 02:17:03
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Sold by Corebridge Financial Inc.
Corebridge Financial Inc. reduced its position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) by 7.0% in the 4th quarter, Holdings Channel reports. The fund owned 8,574 shares of the company’s stock after selling 646 shares during the period. Corebridge Financial Inc.’s holdings in Praxis Precision Medicines were worth $660,000 at the end of […] - 2025-04-07 04:32:48
US Bancorp DE Lowers Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)
US Bancorp DE reduced its stake in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) by 57.7% during the 4th quarter, HoldingsChannel reports. The fund owned 968 shares of the company’s stock after selling 1,321 shares during the period. US Bancorp DE’s holdings in Praxis Precision Medicines were worth $74,000 at the end […] - 2025-03-18 05:13:01
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year Low After Analyst Downgrade
Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report) reached a new 52-week low during trading on Tuesday after Wedbush downgraded the stock from a hold rating to a strong sell rating. The stock traded as low as $30.01 and last traded at $32.63, with a volume of 94961 shares traded. The stock […] - 2025-03-06 05:08:14
New York State Common Retirement Fund Has $604,000 Stock Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)
New York State Common Retirement Fund raised its position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) by 12.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 7,847 shares of the company’s stock after buying an additional 847 shares during the period. New York State […] - 2025-03-05 09:01:03
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Stock Holdings Decreased by Rhumbline Advisers
Rhumbline Advisers decreased its stake in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) by 1.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 22,769 shares of the company’s stock after selling 347 shares during the period. Rhumbline Advisers’ holdings in Praxis Precision […] - 2025-03-05 08:08:59
HC Wainwright Has Lowered Expectations for Praxis Precision Medicines (NASDAQ:PRAX) Stock Price
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) had its price objective decreased by stock analysts at HC Wainwright from $120.00 to $105.00 in a report released on Monday, Marketbeat Ratings reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 189.98% from the […] - 2025-03-05 05:04:58
Needham & Company LLC Lowers Praxis Precision Medicines (NASDAQ:PRAX) Price Target to $85.00
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) had its price target cut by investment analysts at Needham & Company LLC from $150.00 to $85.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s price objective indicates a […] - 2025-03-05 05:04:55
Truist Financial Cuts Praxis Precision Medicines (NASDAQ:PRAX) Price Target to $85.00
Praxis Precision Medicines (NASDAQ:PRAX – Free Report) had its price objective trimmed by Truist Financial from $175.00 to $85.00 in a research note released on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. Several other research analysts have also issued reports on PRAX. Needham & Company LLC cut their target […] - 2025-03-04 04:52:56
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives $145.20 Average Target Price from Brokerages
Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report) has been given a consensus rating of “Moderate Buy” by the ten research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average twelve-month […] - 2025-02-26 04:23:00
Deutsche Bank Aktiengesellschaft Initiates Coverage on Praxis Precision Medicines (NASDAQ:PRAX)
Deutsche Bank Aktiengesellschaft assumed coverage on shares of Praxis Precision Medicines (NASDAQ:PRAX – Free Report) in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $111.00 price target on the stock. A number of other research firms have also commented on PRAX. Oppenheimer increased their […] - 2025-02-14 06:32:53

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc PRAX holdings

DateNumber of PRAX Shares HeldBase Market Value of PRAX SharesLocal Market Value of PRAX SharesChange in PRAX Shares HeldChange in PRAX Base ValueCurrent Price per PRAX Share HeldPrevious Price per PRAX Share Held
2025-09-26 (Friday)1,890USD 99,112USD 99,112
2025-09-25 (Thursday)1,890USD 93,083PRAX holding increased by 530USD 93,0830USD 530 USD 49.2503 USD 48.9698
2025-09-24 (Wednesday)1,890USD 92,553USD 92,553
2025-09-17 (Wednesday)1,878USD 82,688PRAX holding increased by 3812USD 82,6880USD 3,812 USD 44.0298 USD 42
2025-09-16 (Tuesday)1,878USD 78,876USD 78,876
2025-09-12 (Friday)1,866USD 70,358USD 70,358
2025-09-11 (Thursday)1,866PRAX holding increased by 24USD 73,558PRAX holding decreased by -1504USD 73,55824USD -1,504 USD 39.4202 USD 40.7503
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of PRAX by Blackrock for IE00B3VWM098

Show aggregate share trades of PRAX

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-09-11BUY24 39.420* 53.62
2025-08-21SELL-6 46.380* 53.66 Profit of 322 on sale
2025-07-31BUY18 54.220* 53.71
2025-06-30SELL-12 42.050* 54.03 Profit of 648 on sale
2025-06-25SELL-6 43.330* 54.25 Profit of 326 on sale
2025-06-20SELL-12 42.340* 54.50 Profit of 654 on sale
2025-05-23BUY6 37.550* 56.63
2025-05-19SELL-6 37.350* 57.26 Profit of 344 on sale
2025-05-15SELL-18 37.200* 57.61 Profit of 1,037 on sale
2025-05-12SELL-6 38.420* 58.15 Profit of 349 on sale
2025-05-09SELL-6 38.350* 58.33 Profit of 350 on sale
2025-04-30SELL-6 37.640* 59.69 Profit of 358 on sale
2025-04-24SELL-12 36.000* 60.62 Profit of 727 on sale
2025-04-17SELL-6 33.790* 61.97 Profit of 372 on sale
2025-04-15SELL-18 29.670* 62.66 Profit of 1,128 on sale
2025-04-14SELL-18 29.750* 63.02 Profit of 1,134 on sale
2025-04-09SELL-24 30.850* 64.14 Profit of 1,539 on sale
2025-04-07SELL-42 31.530* 64.93 Profit of 2,727 on sale
2025-04-04SELL-60 32.650* 65.30 Profit of 3,918 on sale
2025-03-31BUY6 37.870* 66.33
2025-03-19SELL-12 38.620* 69.36 Profit of 832 on sale
2025-03-14SELL-36 38.280* 70.67 Profit of 2,544 on sale
2025-03-13SELL-12 37.290* 71.14 Profit of 854 on sale
2025-03-12SELL-204 38.570* 71.61 Profit of 14,608 on sale
2025-03-07SELL-12 38.500* 73.14 Profit of 878 on sale
2025-03-06SELL-18 37.870* 73.67 Profit of 1,326 on sale
2025-03-03SELL-6 33.550* 75.47 Profit of 453 on sale
2025-02-26SELL-6 68.390* 76.38 Profit of 458 on sale
2025-02-25SELL-18 66.890* 76.54 Profit of 1,378 on sale
2025-02-18BUY30 78.650* 76.49
2025-02-13BUY6 86.660* 75.72
2025-02-12BUY6 85.400* 75.52
2025-02-11BUY18 84.240* 75.34
2025-02-06BUY54 87.410* 74.60
2025-01-27BUY6 73.300* 73.78
2024-12-30BUY30 76.260* 73.31
2024-12-06BUY24 69.850* 73.77
2024-12-05BUY6 68.130* 73.96
2024-12-04BUY30 74.200* 73.95
2024-11-29BUY30 80.170* 73.62
2024-11-27BUY24 79.450* 73.11
2024-11-26BUY6 79.660* 72.82
2024-11-21BUY30 73.060* 72.62
2024-11-20BUY18 73.680* 72.56
2024-11-18BUY72 71.510* 72.61
2024-11-12BUY48 82.970* 71.92
2024-11-08BUY30 77.875* 71.50
2024-11-07BUY90 75.350* 71.20
2024-11-06BUY12 71.870* 71.14
2024-10-31BUY6 69.990* 71.58
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of PRAX

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-1947,425067,18270.6%
2025-09-1888,2730115,15776.7%
2025-09-17130,62711178,53273.2%
2025-09-1669,1075116,73759.2%
2025-09-1570,7100102,44369.0%
2025-09-1246,7620117,32839.9%
2025-09-1146,883083,09356.4%
2025-09-1044,317091,28948.5%
2025-09-09142,3811,051267,52153.2%
2025-09-08500,1713,037796,05562.8%
2025-09-0546,0060105,70143.5%
2025-09-0434,09142053,77463.4%
2025-09-0359,8200133,99344.6%
2025-09-0233,744083,03140.6%
2025-08-2935,8540112,19532.0%
2025-08-2824,421073,40133.3%
2025-08-2751,2110172,11629.8%
2025-08-2636,214064,29656.3%
2025-08-2543,209061,80569.9%
2025-08-2242,5020110,46638.5%
2025-08-2125,300049,87950.7%
2025-08-2038,6950101,80738.0%
2025-08-1974,4970132,62256.2%
2025-08-1895,7950573,24316.7%
2025-08-1545,573081,94155.6%
2025-08-1444,898079,37556.6%
2025-08-1334,8540192,11118.1%
2025-08-1281,5970218,06437.4%
2025-08-11120,8410374,07132.3%
2025-08-08111,1390183,05960.7%
2025-08-0749,684076,03065.3%
2025-08-06106,5440181,87058.6%
2025-08-05180,7652,134289,06562.5%
2025-08-04298,6595,949564,91252.9%
2025-08-0185,0340249,94434.0%
2025-07-3166,32615184,79335.9%
2025-07-3083,2510212,47639.2%
2025-07-2979,72440183,74443.4%
2025-07-2881,7629148,82754.9%
2025-07-25107,38877190,85656.3%
2025-07-2487,402423176,98449.4%
2025-07-2384,7600208,64740.6%
2025-07-22124,4130184,69267.4%
2025-07-2192,01580200,24946.0%
2025-07-1856,726254187,17230.3%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.